The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/Objective-Atherosclerosis and restenosis are multifactorial diseases associated with abnormal vascular smooth muscle cell (VSMC) proliferation. Nuclear factor-Y (NF-Y) plays a major role in transcriptional activation of the CYCLIN B1 gene (CCNB1), a key positive regulator of cell proliferation and neointimal thickening. Here, we investigated the role of NF-Y in occlusive vascular disease. Approach and Results-We performed molecular and expression studies in cultured cells, animal models, and human tissues. We find upregulation of NF-Y and cyclin B1 expression in proliferative regions of murine atherosclerotic plaques and mechanically induced lesions, which correlates with higher binding of NF-Y to target sequences in the CCNB1 promoter. NF-YA expression in neointimal lesions is detected in VSMCs, macrophages, and endothelial cells. Plateletderived growth factor-BB, a main inductor of VSMC growth and neointima development, induces the recruitment of NF-Y to the CCNB1 promoter and augments both CCNB1 mRNA expression and cell proliferation through extracellular signal-regulated kinase 1/2 and Akt activation in rat and human VSMCs. Moreover, adenovirus-mediated overexpression of a NF-YA-dominant negative mutant inhibits platelet-derived growth factor-BB-induced CCNB1 expression and VSMC proliferation in vitro and neointimal lesion formation in a mouse model of femoral artery injury. We also detect NF-Y expression and DNA-binding activity in human neointimal lesions. Conclusions-Our results identify NF-Y as a key downstream effector of the platelet-derived growth factor-BB-dependent mitogenic pathway that is activated in experimental and human vasculoproliferative diseases. They also identify NF-Y inhibition as a novel and attractive strategy for the local treatment of neointimal formation induced by vessel denudation. (Arterioscler Thromb Vasc Biol. 2013;33:1036-1045.)
A bnormal cell proliferation is a component of the chronic inflammatory response that promotes atherosclerosis and restenosis post angioplasty. 1, 2 Studies with genetically modified mice have shown that ablation of the growth suppressors p53, p27, and pRb aggravates atherosclerosis in hypercholesterolemic mice. 1, 3 Gene therapy strategies that inhibit positive cell-cycle regulators (eg, cyclin-dependent kinases and cyclins) or upregulate growth suppressors (eg, p16, p21, p27, p53, p57, and RB2/p130) have also proved efficient at reducing neointimal thickening in animal models of atherosclerosis and restenosis. 1, 3 Importantly, the incidence of clinical restenosis is significantly diminished by the use of stents that locally deliver antiproliferative drugs. 2 Cell proliferation requires the sequential activation of cyclin-dependent kinase/cyclin complexes. 4 Expression of cyclin B1 (encoded by the CCNB1 gene), which is essential for progression through mitosis and for mouse embryonic development, 5 is induced in the rat carotid artery model of balloon angioplasty. 6 Moreover, inhibition of CCNB1 by local delivery of antisense oligonucleotides reduces neointima formation in this animal model. 7 Identification of the mechanisms that control CCNB1 expression in the vasculature may, therefore, provide insight into the pathogenesis of atherosclerotic disease. The CCNB1 promoter contains 2 CCAAT sites located at positions −17/−13 and +16/+20 relative to the transcription start site that are essential for CCNB1 transcription during the G2/M cell-cycle transition. 8, 9 These CCAAT motifs bind nuclear factor-Y (nuclear factor-Y [NF-Y], also called CBF: CCAAT-binding factor), a ubiquitously expressed trimeric transcription factor formed from NF-YA, NF-YB, and NF-YC subunits. 10 CCAAT boxes are present in ≈25% of eukaryotic genes, and cell culture experiments demonstrate that NF-Y is required for the proliferation of fibroblasts and tumor cells. [9] [10] [11] [12] [13] However, the expression and function of NF-Y in the context of vascular pathophysiology has not been reported. Here, we hypothesized that NF-Y activation is important for the proliferative response associated with atherosclerosis and restenosis. To test this hypothesis, we performed expression and molecular studies using cultures of rat and human vascular smooth muscle cells (VSMCs), animal models (rat carotid artery balloon angioplasty and apolipoprotein E-null mouse: apoE-KO), and human atherosclerotic and restenotic tissue. We also analyzed the consequences of inactivating NF-Y on VSMC proliferation in vitro and vascular lesion formation in a mouse model of femoral artery injury.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

NF-Y Activation in Mechanically-Injured Rat Arteries
We investigated NF-Y expression and activity in animal models of vasculoproliferative disease. First, we analyzed the expression of NF-YA in balloon-injured rat carotid artery by immunohistochemistry. We also examined the expression of cyclin B1 and proliferating cell nuclear antigen, 2 positive regulators of cell proliferation that are induced in this animal model and contribute to neointimal thickening. 6, 7, 14, 15 We found faint expression of these proteins in uninjured vessels (n=4), which was markedly increased in the lesions at early stages (7-12 days post angioplasty; n=5) and advanced stages (14-18 days post angioplasty; n=4) of neointimal thickening ( Figure 1A ). Quantification revealed the following percentages of immunoreactive area in early and advanced neointimal lesions: 33±7% and 29±7% for NF-YA, 28±5% and 30±10% for cyclin B1, and 37±10% and 22±7% for proliferating cell nuclear antigen. Double immunofluorescence staining showed NF-YA/cyclin B1 colocalization in neointimal lesions ( Figure  1B ) and NF-YA expression in neointimal VSMCs ( Figure  1C To investigate the potential contribution of NF-Y to cyclin B1 upregulation after balloon angioplasty, we performed electrophoretic mobility shift assay with a radiolabeled probe spanning the CCAAT-box located at −17/−13 in the CCNB1 promoter. 8 Uninjured rat carotid arteries exhibited no detectable NF-Y DNA-binding activity ( Figure 1D , ln. 2 and 4), but binding progressively increased at 3 days (ln. 3) and 7 days (ln. 5) post angioplasty. The retarded NF-Y probe was efficiently competed out by unlabeled NF-Y consensus oligonucleotide (ln. 6), but not by a NF-Y mutant oligonucleotide with the binding site disrupted (ln. 7). The specificity of the nucleoprotein complex was further confirmed by the supershift produced by preincubation of lysates with anti-NF-YA (ln. 8), but not with isotype-matched control antibody (ln. 9). Mechanically induced neointimal lesions in this animal model thus display abundant NF-YA expression and DNA-binding activity associated with the CCAAT motif at −17/−13 in the CCNB1 promoter.
NF-Y Is a Downstream Effector of the Platelet-Derived Growth Factor-BB Extracellular Signal-Regulated Kinase 1/2-Akt Mitogenic Pathway in VSMCs
Because platelet-derived growth factor-BB (PDGF-BB) potently induces VSMC proliferation in vitro and is essential for neointimal hyperplasia in animal models of balloon angioplasty, 16 we sought to investigate whether NF-Y is a downstream effector of this cytokine. We first performed experiments with rat aortic E19P cells stimulated with PDGF-BB after starvation. Quantitative polymerase chain reaction and chromatin immunoprecipitation assays showed that PDGF-BB significantly induced NF-YA mRNA expression and in vivo recruitment of NF-Y to the CCNB1 promoter, reaching a maximum after 8 hours ( Figure 2A ). This was reflected in the expression of CCNB1 mRNA and S-phase entry at 16 hours, detected by quantitative polymerase chain reaction and 5′-bromo-2′deoxyuridine (BrdU) incorporation, respectively. These 3 parameters returned to basal levels 32 hours after stimulation ( Figure 2A ) and were all significantly blunted by pretreatment of E19P cells with either U0126 (inhibitor of extracellular signal-regulated kinase 1/2 [Erk1/2] activation) or the Akt inhibitor X, but not the p38 inhibitor SB203580 ( Figure 2B ). U0126 and Akt inhibitor X similarly reduced PDGF-BB-dependent NF-Y binding to the CCNB1 promoter, CCNB1 mRNA expression, and cell proliferation in human VSMCs ( Figure 2C ).
Effects of NF-Y Inactivation on Primary VSMCs and Endothelial Cells
We next investigated whether NF-Y activity is involved in CCNB1 expression and proliferation in primary rat and human VSMCs. Cells were infected with either adenoviruscontaining green fluorescent protein (AdGFP), which encodes GFP, or Ad(GFP+NF-YAdn), which gives rise to a bicistronic mRNA encoding both GFP and a dominant negative mutant NF-YA13m29 that inhibits NF-Y activity. 17 Ad(GFP+NF-YAdn)-infected rat VSMCs overexpressed NF-YA13m29 ( Figure 3A ) and exhibited reduced NF-Y DNA-binding activity ( Figure 3B , ln. 4 versus 2 and 3). Moreover, compared with control AdGFP, Ad(GFP+NF-YAdn) impaired fetal bovine serum-dependent upregulation of CCNB1 mRNA and BrdU incorporation in rat VSMCs ( Figure 3C ). Infection of human VSMCs with Ad(GFP+NF-YAdn) also reduced PDGF-BBdependent CCNB1 mRNA expression and proliferation ( Figure  3D ). We also found a slight but significant increase in apoptosis in Ad(GFP+NF-YAdn)-infected rat VSMCs compared with AdGFP-infected controls ( Figure IIIA 
Inhibition of NF-Y Activity Reduces Neointimal Thickening Induced by Arterial Denudation
To assess the effects of inhibiting NF-Y on neointimal thickening in vivo, we performed gene therapy studies using a mouse model of femoral artery wire injury. Immediately after injury, Ad(GFP+NF-YAdn) or control AdGFP was infused intraluminally and arteries were exposed to the virus for 20 minutes. Arteries were removed 9 days after denudation. Effective gene delivery was demonstrated by the presence of GFP-immunoreactive cells in arteries infected with either viral vector, but not in control (uninfected, uninjured) vessels ( Figure 4A ). To examine the effect of NF-YAdn expression on DNA-binding activity, we performed electrophoretic mobility shift assays with arterial lysates and a probe containing the NF-Y binding site at −17/−13 in the CCNB1 promoter. Control experiments using lysates from AdGFP-infected arteries revealed a retarded nucleoprotein complex that was abrogated with either unlabeled NF-Y consensus oligonucleotide or anti-NF-YA antibody, but not with NF-Y mutant oligonucleotide or anti-CREBII ( Figure 4B ). In agreement with the results in the rat carotid artery angioplasty model ( Figure 1D ), NF-Y DNAbinding activity was undetectable in uninjured mouse femoral arteries and was markedly upregulated in injured vessels 7) were performed with unlabeled NF-Ycons or mutated (NF-Ymut) oligonucleotide. For supershift assays (ln. 8, 9) , extracts were preincubated with antibodies. PCNA indicates proliferating cell nuclear antigen.
( Figure 4C , ln. 2 versus 3). Importantly, ectopic expression of NF-YAdn significantly reduced injury-induced DNA-binding activity ( Figure 4C , ln. 3 versus 4) and inhibited neointimal thickening (47% reduction in intima:media ratio; P=0.002) without significantly affecting medial area ( Figure 4D ).
NF-Y Activation in Mouse Atherosclerotic Lesions
We also studied the role of NF-Y in native atherosclerosis by performing immunohistochemical analysis in atherosclerosisprone apoE-KO mice and wild-type controls ( Figure 5A ). Expression of NF-YA, cyclin B1, and the proliferation marker Ki67 was faint in cross-sections of nonatherosclerotic aortas from wild-type and apoE-KO mice-fed control diet. In marked contrast, atherosclerotic lesions of fat-fed apoE-KO mice contained areas that were immunoreactive for these proteins (NF-YA: 30±4%; cyclin B1: 25±2%; Ki67: 9±2%), which were also expressed in spontaneously formed lesions in older apoE-KO mice-fed control chow (not shown). Double immunofluorescence experiments in aorta from fat-fed apoE-KO mice revealed abundant NF-YA expression in neointimal macrophages and VSMCs, which are the predominant cells in the atheroma ( Figure 5B ). Moreover, these cells express cyclin B1, as revealed by double immunohistochemical analysis ( Figure IV in the online-only Data Supplement). We also find NF-YA expression in endothelial cells lining atherosclerotic lesions ( Figure IC in the online-only Data Supplement). We next performed electrophoretic mobility shift assay using the NF-Y binding site at −17/−13 in the CCNB1 promoter, which revealed increased NF-Y DNA-binding activity in the atherosclerotic aortic arch and thoracic aorta of apoE-KO mice ( Figure 5C 
NF-Y Activation in Human Restenotic and Atherosclerotic Lesions
To address the clinical relevance of our findings, we performed pilot immunohistochemistry studies to analyze NF-YA expression in human restenotic and atherosclerotic vessels. In human restenotic coronary artery tissue obtained by percutaneous directional atherectomy, NF-YA was detected in 9 of 10 specimens analyzed, with varying degrees of expression among the different patients ( Figure 6A ). The analysis of consecutive sections of human restenotic tissue revealed regions with abundant NF-YA and cyclin B1 expression ( Figure 6B) . We also detected NF-YA in 7 of 8 human atherosclerotic coronary artery specimens ( Figure 6C ). The analysis of consecutive sections showed regions with abundant NF-YA and cyclin B1 expression ( Figure 6D ), and double immunofluorescence studies revealed NF-YA expression in neointimal VSMCs and endothelial cells lining the lesions ( Figure V in the online-only Data Supplement). As shown in Figure 6E , human atherosclerotic coronary arteries (ln. 12-16) also exhibited increased NF-Y DNA-binding activity compared with control internal mammary arteries (ln. 2-6) and coronary arteries (ln. 7-11; 7.6±1.3-fold increase; P<0.001). Specificity of the retarded nucleoprotein complexes was demonstrated by competition and supershift assays ( Figure 6F ).
Discussion
Cyclin B1 is essential for cell-cycle progression and its genetic disruption in the mouse causes embryonic lethality. 5 Under normal conditions, cyclin B1 expression is tightly regulated to ensure that it accumulates appreciably only during the G2/M cell-cycle transition. 9 Aberrantly, high levels of cyclin B1 throughout the cell cycle as a result of deregulated gene transcription is associated with excessive cell proliferation in several human cancers. 18 Moreover, expression of cyclin B1 is induced in balloon-injured rat carotid artery, 6 and local delivery of antisense oligonucleotides against CCNB1 inhibits neointima formation in a rat carotid artery model of balloon angioplasty. 7 Although these results highlight the role of CCNB1 in promoting mechanically induced neointimal thickening, the mechanisms that regulate its expression in vascular cells remain elusive. In the present study, we hypothesized that induction of the heterotrimeric transcription factor NF-Y, acting through increasing CCNB1 expression, is important for neointimal thickening. We focused on NF-YA because NF-Y activity is mainly controlled through changes in NF-YA protein expression and post-translational modifications. 10 By combining cell culture experiments and studies with animal models and human specimens, we provide evidence that NF-Y plays an important role in inducing cyclin B1 expression and VSMC proliferation in atherosclerotic and restenotic lesions (Figure 7) . We have shown that balloon angioplasty in the rat carotid artery causes a temporally and spatially coordinated expression of NF-YA and cyclin B1 in neointimal lesions with proliferative activity. Using this model and a mouse model of arterial wire injury, we also find a marked upregulation of NF-Y DNA-binding activity in the damaged vessel wall. Likewise, expression of NF-YA, cyclin B1, and the proliferation marker Ki67 is upregulated in atheromata of apoE-KO mice, and this is accompanied by a marked increase in NF-Y DNA-binding activity compared with nonatherosclerotic tissue. NF-Y-dependent induction of cyclin B1 expression may also contribute to neointimal cell proliferation in patients because our pilot studies revealed expression of both proteins in human atherosclerotic and restenotic tissue, as well as increased NF-Y DNA binding to its target sequence in the CCNB1 promoter in atherosclerotic coronary arteries compared with control vessels. Future studies are thus warranted to further investigate the expression and activity of NF-Y in a larger set of human occlusive vascular lesions. Our studies revealed expression of NF-YA in neointimal VSMCs and macrophages and in endothelial cells lining neointimal lesions. Interestingly, we find that adenovirusmediated NF-Y inhibition does not affect endothelial cell proliferation and apoptosis in vitro. It will be important to ascertain whether NF-Y exerts cell-cycle-independent and apoptosis-independent actions in vascular endothelial cells and neointimal macrophages. For example, given that NF-Y regulates myeloid differentiation, 19 studies are warranted to investigate its role in macrophage inflammatory response, including cytokine production, phagocytic activity, and lipoprotein uptake. Future studies should also address whether NF-Y expression/activity in vascular cells and macrophages is regulated by lipid-modulating and anti-inflammatory strategies recently developed to treat atherosclerosis 20 and to ascertain whether these new therapies may cooperate with anti-NF-Y approaches.
Consistent with previous studies in fibroblasts and tumor cells that demonstrated reduced CCNB1 expression and cell proliferation on inhibition of NF-Y DNA-binding activity, [11] [12] [13] 21 we find that NF-Y inhibition in cultures of VSMCs reduces mitogen-induced CCNB1 expression and cell proliferation. The in vivo relevance of these results is further highlighted by the observation that intraluminal delivery of adenovirus encoding the dominant negative NF-YA mutant inhibits NF-Y DNA-binding activity and neointima development in a mouse model of arterial injury. Cell proliferation occurs mainly at early stages of vascular remodeling induced by mechanical injury. 3 We found no differences in neointimal Ki67 immunoreactivity in arteries infected with Ad(GFP+NF-YAdn) at the time point analyzed for lesion quantification ( Figure IIIB in the online-only Data Supplement), which corresponds to an advanced stage of disease progression. These results suggest that NF-Y inhibits VSMC proliferation during the first days after vessel denudation. Given that apoptotic cell death also occurs in mechanically injured arteries, we also analyzed the effect of NF-YA inactivation on apoptosis.
Although we found a modest increase in apoptosis of primary VSMCs infected with Ad(GFP+NF-YAdn), NF-YA inactivation did not affect apoptosis in mouse femoral neointimal lesions and in primary endothelial cell cultures. Studies in animal models of atherosclerosis and arterial denudation have conclusively demonstrated that neointimal thickening is significantly dependent on PDGF signaling, and both PDGF-BB and its receptor PDGFR-β are expressed in atherosclerotic and restenotic lesions in experimental animals and humans. 16 It is now recognized that the Erk1/2 and Akt signaling cascades are downstream effectors of PDGF in VSMCs 22-24 that stimulate neointimal thickening after vascular injury, 25, 26 The results of our quantitative polymerase chain reaction and chromatin immunoprecipitation studies demonstrate that PDGF-BB induces NF-Y expression and its recruitment to the endogenous CCNB1 promoter in rat and human VSMCs, and this is followed by increased CCNB1 mRNA expression and cell proliferation. These responses to PDGF-BB are impaired on treatment with pharmacological inhibitors of either Erk1/2 or Akt or by NF-YA-dominant negative mutant overexpression. Collectively, our results identify NF-Y as an important downstream mediator in the PDGF-BB-Erk1/2-Akt-dependent signaling cascade that contributes to neointimal thickening through the induction of CCNB1 expression and VSMC proliferation (Figure 7 ). It is, therefore, possible that inhibiting NF-Y would offer a more specific and safer strategy than targeting its upstream effectors Akt and Erk1/2, which control multiple physiological processes that are essential for the maintenance of cellular and organismal homeostasis (eg, differentiation, motility, apoptosis, autophagy, angiogenesis, metabolism, and protein synthesis). 27, 28 In this regard, the pyrrolobenzodiazepinepolyamide conjugate GWL-78 has been shown to displace NF-Y from several CCAAT motifs within promoters of cellcycle genes and to block fibroblast proliferation. 13 Preclinical studies in large animal models are thus warranted to explore the efficacy of GWL-78 at preventing neointimal thickening. In summary, our results show that the transcription factor NF-Y is induced in experimental and human atherosclerosis and restenosis. We also find that adenovirus-mediated inactivation of NF-Y attenuates PDGF-BB-induced VSMC proliferation in vitro and the development of neointimal lesions in a mouse model of vascular injury. We therefore propose that NF-Y is an attractive novel target for intervention in atherosclerosis and restenosis, as well as other vascular-remodeling diseases that display VSMC proliferation (eg, transplant atherosclerosis and pulmonary hypertension). 
